Uppsala and Garching/Munich, August 20, 2026
Akiram Therapeutics has entered into a Lutetium-177 (Lu-177) supply agreement with ITM Isotope Technologies Munich SE to support the continued clinical development of AKIR001, the company’s targeted antibody-radionuclide conjugate being investigated for CD44v6-expressing solid tumors. Under the agreement, ITM will supply non-carrier-added (n.c.a.) Lu-177, the therapeutic radioisotope used as the active payload in AKIR001. For Akiram, securing a dependable isotope supply represents an important development and manufacturing step as the company advances its lead radiopharmaceutical candidate through clinical testing. The agreement specifically supports Akiram’s ongoing clinical trial program and strengthens the operational foundation required for continued development of AKIR001. While financial and other commercial terms were not disclosed, the partnership highlights the importance of reliable medical radioisotope supply in the development of targeted radiopharmaceutical therapies. ITM’s established expertise in the production and supply of n.c.a. Lu-177 provides Akiram with access to a key component required for its clinical-stage program, while the agreement further connects the Swedish biotech with an established radiopharmaceutical manufacturing and supply network. The supply partnership is therefore primarily focused on enabling uninterrupted clinical development of AKIR001, rather than representing a licensing or co-development transaction.
Lu-177 Supply Supports AKIR001 Clinical Development
AKIR001 is designed as a targeted radiopharmaceutical combining n.c.a. Lu-177 with Akiram’s proprietary antibody directed against CD44v6, a cancer marker associated with several aggressive tumor types. The treatment strategy is intended to direct the radioactive payload toward cancer cells expressing CD44v6, with the objective of delivering therapeutic radiation more selectively to tumor tissue while limiting exposure to healthy tissue. The availability of high-quality Lu-177 is a critical component of this development strategy, because the isotope serves as the therapeutic payload within AKIR001. By establishing a dedicated supply relationship with ITM, Akiram is addressing an important infrastructure requirement for its clinical program. The agreement comes as radiopharmaceutical development increasingly depends not only on promising targeting technologies but also on consistent access to medical isotopes, specialized manufacturing capabilities and dependable supply chains. For cGxP.wire readers following radiopharmaceutical manufacturing, clinical development and oncology partnerships, the agreement provides a clear example of how isotope suppliers and emerging biotechnology companies are connecting to support the advancement of next-generation targeted cancer therapies. The collaboration also demonstrates how supply arrangements can become an important part of the broader development pathway for radiopharmaceutical candidates.
AKIR001 Targets CD44v6-Positive Solid Tumors
AKIR001 is currently being evaluated in a Phase I clinical trial, NCT06639191, at Karolinska University Hospital in Stockholm, focusing on patients with irresectable or metastatic CD44v6-positive solid tumors. The clinical program includes tumor types such as lung, head and neck, thyroid and gynecological cancers, where CD44v6 may provide a potential target for selective radiopharmaceutical treatment. At this stage, the most important development objective is establishing the candidate’s clinical profile and determining whether the targeted approach can demonstrate an acceptable safety and therapeutic potential in patients. The Lu-177 agreement directly supports this clinical-development infrastructure by helping ensure access to the radioactive component required for AKIR001 production and administration. Akiram describes AKIR001 as having potential to become a first-in-class targeted therapy, although that positioning remains dependent on clinical evidence and future development outcomes. The current agreement does not provide clinical efficacy results or regulatory approval information, and therefore its immediate significance is operational: it strengthens the supply framework supporting an active Phase I radiopharmaceutical program. This makes the agreement relevant to the broader biopharma ecosystem surrounding targeted radionuclide therapy, particularly as companies seek scalable and reliable sources of therapeutic isotopes.
Advertisement
ITM Strengthens Radiopharmaceutical Supply Partnership
For ITM Isotope Technologies Munich, the agreement expands its role in supporting the development of innovative radiopharmaceutical programs through the supply of n.c.a. Lu-177. Lu-177 is among the most widely used medical radioisotopes in targeted radionuclide therapy and is increasingly important across precision oncology programs. ITM has built its business around the development, production and global supply of medical radioisotopes and radiopharmaceutical products, making isotope availability a central component of its contribution to the sector. For Akiram, the partnership provides access to an established supplier while its lead candidate moves through clinical development. The agreement does not disclose financial terms, manufacturing volumes or additional commercial commitments, keeping the announcement focused on supply support for the current AKIR001 program. From a cGxP.wire perspective, the development is significant because it illustrates the growing importance of radiopharmaceutical supply chains, isotope manufacturing and clinical-stage partnerships in precision oncology. As targeted radionuclide therapies continue to advance, reliable access to therapeutic isotopes such as Lu-177 is becoming an increasingly important factor in translating innovative drug candidates from development programs into clinical testing. Akiram and ITM’s agreement therefore represents a focused supply collaboration supporting the next stage of AKIR001’s clinical development in solid tumors.
Source:Akiram Therapeutics,, press relese
